Mastitia announced the spin-out story for dVO - de Vlaamse Ondernemer

Breastfeeding is vital for infant health and recommended by WHO as the sole source of nutrition for the first 6 months of life. Yet, millions of mothers face mastitis - a painful breast inflammation affecting 1 in 4 breastfeeding women worldwide. Up to 38% are forced to stop breastfeeding early, despite its critical role in infant nutrition. Today, standard care relies mainly on antibiotics, potentially exposing over 30 million infants annually to antibiotic transfer through breast milk. Early weaning and antibiotic exposure can disrupt infant microbiomes, raising risks of allergies, immune disorders, and long-term health complications. Mastitia is changing this. We are developing an effective, microbiome-friendly solution for mastitis care - helping mothers continue breastfeeding while reducing dependence on antibiotics. Our innovation supports WHO’s sustainable development goals by improving maternal and infant health while combating antimicrobial resistance. Together, let’s safeguard breastfeeding and improve global health for mothers and infants!